Alliancebernstein L.P. Sells 151,818 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Alliancebernstein L.P. decreased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 12.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,056,520 shares of the biopharmaceutical company's stock after selling 151,818 shares during the quarter. Alliancebernstein L.P. owned approximately 0.99% of Intra-Cellular Therapies worth $88,241,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ITCI. China Universal Asset Management Co. Ltd. boosted its stake in shares of Intra-Cellular Therapies by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock valued at $1,878,000 after purchasing an additional 2,157 shares during the last quarter. Barclays PLC lifted its holdings in Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock valued at $2,521,000 after buying an additional 25,435 shares during the period. Oak Ridge Investments LLC boosted its stake in Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock valued at $1,656,000 after acquiring an additional 8,440 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Intra-Cellular Therapies by 3.3% during the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock worth $43,735,000 after acquiring an additional 18,865 shares during the period. Finally, Merit Financial Group LLC bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter valued at $206,000. Institutional investors and hedge funds own 92.33% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Cantor Fitzgerald restated a "neutral" rating and issued a $132.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and lifted their price objective for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, Mizuho cut shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and decreased their price objective for the company from $140.00 to $132.00 in a report on Monday, February 24th. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, Intra-Cellular Therapies has a consensus rating of "Hold" and a consensus price target of $106.23.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock remained flat at $131.87 during trading hours on Tuesday. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.98. The company has a 50-day moving average of $129.71 and a 200 day moving average of $102.19. The firm has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. As a group, equities research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.